文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Winzeler S, Rosenstein B D

ASMT Health Services, CibaVision Corporation, Atlanta, GA, USA.

AAOHN J. 1998 May;46(5):253-9; quiz 260-1.

Non-steroidal antiinflammatory drugs (NSAIDs) are among the most frequently prescribed medications and are used primarily to control pain, stiffness, and reduce inflammation. 2. One of the most common adverse effects of NSAID therapy is gastrointestinal (GI) problems, specifically indigestion, nausea, dyspepsia, diarrhea, constipation, and gastritis. 3. Considerations in chronic pain management include non-pharmacologic treatment options (i.e., physical therapy, behavioral therapy, etc.), use of misoprostol for clients at high risk for NSAID induced GI problems, and monitoring blood and urine every 3 months to 1 year with chronic NSAID therapy to detect liver, kidney, and hematologic problems. 4. Current research is focused on development of a prostaglandin H synthetase (PGHS-2) inhibitor which should offer efficacy equal to the most potent NSAIDs with minimal side effects, including gastric safety.

非甾体抗炎药（NSAIDs）是最常开具的药物之一，主要用于控制疼痛、僵硬和减轻炎症。2. NSAID治疗最常见的不良反应之一是胃肠道（GI）问题，特别是消化不良、恶心、消化不良、腹泻、便秘和胃炎。3. 慢性疼痛管理的考虑因素包括非药物治疗选择（即物理治疗、行为治疗等），对于有NSAID诱发GI问题高风险的患者使用米索前列醇，以及在慢性NSAID治疗期间每3个月至1年监测血液和尿液以检测肝脏、肾脏和血液学问题。4. 当前的研究集中在开发一种前列腺素H合成酶（PGHS-2）抑制剂，该抑制剂应具有与最有效的NSAIDs相当的疗效，且副作用最小，包括胃部安全性。

Winzeler S, Rosenstein B D

ASMT Health Services, CibaVision Corporation, Atlanta, GA, USA.

AAOHN J. 1998 May;46(5):253-9; quiz 260-1.

Non-steroidal antiinflammatory drugs (NSAIDs) are among the most frequently prescribed medications and are used primarily to control pain, stiffness, and reduce inflammation. 2. One of the most common adverse effects of NSAID therapy is gastrointestinal (GI) problems, specifically indigestion, nausea, dyspepsia, diarrhea, constipation, and gastritis. 3. Considerations in chronic pain management include non-pharmacologic treatment options (i.e., physical therapy, behavioral therapy, etc.), use of misoprostol for clients at high risk for NSAID induced GI problems, and monitoring blood and urine every 3 months to 1 year with chronic NSAID therapy to detect liver, kidney, and hematologic problems. 4. Current research is focused on development of a prostaglandin H synthetase (PGHS-2) inhibitor which should offer efficacy equal to the most potent NSAIDs with minimal side effects, including gastric safety.

非甾体抗炎药（NSAIDs）是最常开具的药物之一，主要用于控制疼痛、僵硬和减轻炎症。2. NSAID治疗最常见的不良反应之一是胃肠道（GI）问题，特别是消化不良、恶心、消化不良、腹泻、便秘和胃炎。3. 慢性疼痛管理的考虑因素包括非药物治疗选择（即物理治疗、行为治疗等），对于有NSAID诱发GI问题高风险的患者使用米索前列醇，以及在慢性NSAID治疗期间每3个月至1年监测血液和尿液以检测肝脏、肾脏和血液学问题。4. 当前的研究集中在开发一种前列腺素H合成酶（PGHS-2）抑制剂，该抑制剂应具有与最有效的NSAIDs相当的疗效，且副作用最小，包括胃部安全性。